SHRX Share Price Performance
Recent SHRX News & Updates
No updates
Sharp Therapeutics Corp. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.18
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Sharp Therapeutics Corp. Competitors
About SHRX
- Founded
- n/a
- Employees
- n/a
- CEO
- WebsiteView website
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a proprietary IP-protected analytics platform that captures all data for all AlloChem compounds in all CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.
U.S. Market Performance
- 7 Days: 1.0%
- 3 Months: 15.8%
- 1 Year: 18.0%
- Year to Date: 8.1%
In the last week, the market has been flat. Meanwhile, the market is actually up 18% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading